Inst

Core Molding Technologies Appoints New Board Member

Retrieved on: 
Thursday, November 2, 2023
Knowledge, Core Molding Technologies, NYSE, Libbey, MBA, Industrial engineering, Core, University, University of Southern California, CMT, Management, Inst

COLUMBUS, Ohio, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Core Molding Technologies, Inc. (NYSE American: CMT) (“Core Molding”, “Core” or the “Company”), announced today that Salvador Miñarro has been appointed to its Board of Directors.

Key Points: 
  • COLUMBUS, Ohio, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Core Molding Technologies, Inc. (NYSE American: CMT) (“Core Molding”, “Core” or the “Company”), announced today that Salvador Miñarro has been appointed to its Board of Directors.
  • Mr. Miñarro is the Chief Executive Officer of Darnel Group, a global leader in the production of high-quality, food-grade sustainable packaging solutions and a pioneer in post-consumer recycled material.
  • “We are pleased to have Sal join the Board and look forward to his contributions to the Company.
  • We are excited to have Sal as part of the Core team,” Cellitti continued.

Focusrite Announces 4th Generation Scarlett Interfaces; More Info at B&H

Retrieved on: 
Thursday, August 31, 2023
Technology, Entertainment, Specialty, Audio, Video, Software, Hardware, Music, Retail, Consumer Electronics, XLR, B&H, Multimedia, XLN, Native Instruments, Comment, Direct, Solo, Atmosphere of Earth, USB-C, Risk, Hitmaker, Inst, Cassette tape, Scarlett, Focusrite

B&H is pleased to announce that Focusrite is updating its popular Scarlett lineup of USB-C 24-bit / 192 kHz audio interfaces with new 4th generation models offering updated feature sets geared toward today’s musicians and content creators.

Key Points: 
  • B&H is pleased to announce that Focusrite is updating its popular Scarlett lineup of USB-C 24-bit / 192 kHz audio interfaces with new 4th generation models offering updated feature sets geared toward today’s musicians and content creators.
  • View the full release here: https://www.businesswire.com/news/home/20230831528241/en/
    Focusrite is updating its popular Scarlett lineup of USB-C 24-bit / 192 kHz audio interfaces.
  • (Photo: Business Wire)
    Singer/songwriters and burgeoning creators looking for a cost-effective entry point into Scarlett world should consider the Scarlett Solo and Solo Studio models.
  • All the 4th generation Scarlett interfaces include Pro Tools Artist and Ableton Live Lite recording software.

Serca Pharmaceuticals presents first-in-class strategy for game-changing, post heart-attack cardioprotection at the European Society of Cardiology Congress 2023

Retrieved on: 
Tuesday, August 29, 2023
Infarction, MI, Myocardial infarction, ESC Congress, Heart failure, Disability, Injury, Research, SERCA, Cardioprotection, Patient, Cardiology, Reperfusion, Poster, Congress, Inst, European Society of Cardiology, Death, PPI, IND, Pharmaceutical industry, SERCA2

OSLO, Norway, Aug. 29, 2023 /PRNewswire/ -- Serca Pharmaceuticals, a cardioprotection company that is developing 13-M, a novel first-in-class treatment for minimising the tissue damage that occurs with blood reperfusion post myocardial infarction (MI) and stenting, today presented exciting preclinical data showcasing its novel therapeutic strategy targeting the SERCA2 complex to protect heart tissue from ischemia-reperfusion injury at the European Society of Cardiology Congress 2023, the world's largest cardiology congress, in Amsterdam, The Netherlands, 25–28 August 2023.

Key Points: 
  • The compound could be transformative in treating cardiology patients who are impacted by MI and stenting and is currently in preclinical drug development.
  • MI is one of the leading causes of death and disability worldwide, affecting approximately seven million people each year.
  • For Experimental Medical Research
    For further details on the poster, please contact Tove Flem Jacobsen, or visit the Serca Pharmaceuticals website: https://sercapharmaceuticals.com/ .
  • Company representatives will also be attending the LSX Nordic Congress being held on the 10-11 October and look forward to meeting investors and potential partners.

Serca Pharmaceuticals presents first-in-class strategy for game-changing, post heart-attack cardioprotection at the European Society of Cardiology Congress 2023

Retrieved on: 
Tuesday, August 29, 2023
Infarction, MI, Myocardial infarction, ESC Congress, Heart failure, Disability, Injury, Research, SERCA, Cardioprotection, Patient, Cardiology, Reperfusion, Poster, Congress, Inst, European Society of Cardiology, Death, PPI, IND, Pharmaceutical industry, SERCA2

OSLO, Norway, Aug. 29, 2023 /PRNewswire/ -- Serca Pharmaceuticals, a cardioprotection company that is developing 13-M, a novel first-in-class treatment for minimising the tissue damage that occurs with blood reperfusion post myocardial infarction (MI) and stenting, today presented exciting preclinical data showcasing its novel therapeutic strategy targeting the SERCA2 complex to protect heart tissue from ischemia-reperfusion injury at the European Society of Cardiology Congress 2023, the world's largest cardiology congress, in Amsterdam, The Netherlands, 25–28 August 2023.

Key Points: 
  • The compound could be transformative in treating cardiology patients who are impacted by MI and stenting and is currently in preclinical drug development.
  • MI is one of the leading causes of death and disability worldwide, affecting approximately seven million people each year.
  • For Experimental Medical Research
    For further details on the poster, please contact Tove Flem Jacobsen, or visit the Serca Pharmaceuticals website: https://sercapharmaceuticals.com/ .
  • Company representatives will also be attending the LSX Nordic Congress being held on the 10-11 October and look forward to meeting investors and potential partners.

Serca Pharmaceuticals showcases exciting data on 13-M at Heart Failure 2023

Retrieved on: 
Monday, May 22, 2023
Infarction, MI, Myocardial infarction, Heart failure, Disability, HF, Splenic infarction, Research, Composition of matter, Cytosol, PLB, Cardioprotection, Composition, Patient, PKA, NCE, Poster, PPI, Heart rate, SERCA2, Inst, Death, IND, Pharmaceutical industry

OSLO, Norway, May 22, 2023 /PRNewswire/ -- Serca Pharmaceuticals, a Cardioprotection company that is developing 13-M, a novel first in class treatment for minimising tissue damage that occurs with blood reperfusion post myocardial infarction (MI) and stenting, today announces that it presented data on a novel approach to modulate the Beta-adrenergic receptor-cAMP protein kinase A (PKA) signalling pathway that modulates the contractility at Heart Failure 2023, the world leading event on heart failure, in Prague, Czech Republic, 20-23 May 2023.

Key Points: 
  • OSLO, Norway, May 22, 2023 /PRNewswire/ -- Serca Pharmaceuticals, a Cardioprotection company that is developing 13-M, a novel first in class treatment for minimising tissue damage that occurs with blood reperfusion post myocardial infarction (MI) and stenting, today announces that it presented data on a novel approach to modulate the Beta-adrenergic receptor-cAMP protein kinase A (PKA) signalling pathway that modulates the contractility at Heart Failure 2023 , the world leading event on heart failure, in Prague, Czech Republic, 20-23 May 2023.
  • 13-M is a small NCE shown to have these important protein to protein interaction (PPI) characteristics with the capacity to modulate the SERCA2 Ca2+ pump.
  • MI is one of the leading causes of death and disability worldwide, affecting approximately seven million people each year.
  • Without treatment, 30% of MI patients will go on to develop heart failure.

Serca Pharmaceuticals showcases exciting data on 13-M at Heart Failure 2023

Retrieved on: 
Monday, May 22, 2023
Infarction, MI, Myocardial infarction, Heart failure, Disability, HF, Splenic infarction, Research, Composition of matter, Cytosol, PLB, Cardioprotection, Composition, Patient, PKA, NCE, Poster, PPI, Heart rate, SERCA2, Inst, Death, IND, Pharmaceutical industry

OSLO, Norway, May 22, 2023 /PRNewswire/ -- Serca Pharmaceuticals, a Cardioprotection company that is developing 13-M, a novel first in class treatment for minimising tissue damage that occurs with blood reperfusion post myocardial infarction (MI) and stenting, today announces that it presented data on a novel approach to modulate the Beta-adrenergic receptor-cAMP protein kinase A (PKA) signalling pathway that modulates the contractility at Heart Failure 2023, the world leading event on heart failure, in Prague, Czech Republic, 20-23 May 2023.

Key Points: 
  • OSLO, Norway, May 22, 2023 /PRNewswire/ -- Serca Pharmaceuticals, a Cardioprotection company that is developing 13-M, a novel first in class treatment for minimising tissue damage that occurs with blood reperfusion post myocardial infarction (MI) and stenting, today announces that it presented data on a novel approach to modulate the Beta-adrenergic receptor-cAMP protein kinase A (PKA) signalling pathway that modulates the contractility at Heart Failure 2023 , the world leading event on heart failure, in Prague, Czech Republic, 20-23 May 2023.
  • 13-M is a small NCE shown to have these important protein to protein interaction (PPI) characteristics with the capacity to modulate the SERCA2 Ca2+ pump.
  • MI is one of the leading causes of death and disability worldwide, affecting approximately seven million people each year.
  • Without treatment, 30% of MI patients will go on to develop heart failure.

CareVet Celebrates One Year of The Ultimate CarePackage, Providing Industry-Leading Bonuses & Benefits to Veterinarians

Retrieved on: 
Tuesday, November 29, 2022
DVM, Veterinarian, Hospital, PETS, Patient, Fatigue, Disability, Inst, Ultimate, Miswak, Entrepreneurship, Longevity, Medicine, Veterinary medicine, Health insurance, Tourism

One year after the program was introduced, CareVet continues to build on the program, recruiting and retaining the industry's best talent.

Key Points: 
  • One year after the program was introduced, CareVet continues to build on the program, recruiting and retaining the industry's best talent.
  • To support their Veterinarians, CareVet offers multiple innovative programs under The Ultimate CarePackage .
  • Their Work/Life Balance Program, Carebnb , was released in February of 2022 as a solution to industry-wide burnout.
  • About CareVet: CareVet is a leading operator of independent veterinary hospitals operating in 35+ states with more than 2,500 Team Members.

Munch's Supply, A Marcone Company, Acquires BellSimons

Retrieved on: 
Thursday, November 10, 2022
Ventilation, BMO Capital Markets, Controller, Kohler, Heat, Rheem, Frigidaire, L-G, Goodman, Genstar Capital, Partnership, Mitsubishi, Organization, Technology, Family, Air conditioning, Philosophy, Culture, Trane, American Standard, Inst, CFO, Company, Microwave, Munch, TM Capital Corp., Sylvan Gotshal, HVAC, Samsung, Growth, CEO, A. O. Smith, General Electric, Industry, Acquisition, Heating, ventilation, and air conditioning, Souers, IPEX, Whirlpool, Maytag, Supply, Marcone, Electrolux

NEW LENOX, Ill., Nov. 10, 2022 /PRNewswire/ -- Marcone is pleased to announce that its industry leading heating, ventilation, and air conditioning ("HVAC") division, Munch's Supply (the "Company") has acquired BellSimons, including its 29 branches and three distribution centers in seven states servicing the New England area. This will expand the Company's geographic footprint to 103 locations serving 18 states and the province of Ontario, Canada.

Key Points: 
  • Marcone is a leading technology enabled national distributor of quality home appliance, HVAC, and plumbing parts and equipment to technicians servicing the home.
  • With help from Genstar Capital, Munch's Supply joined the Marcone family of brands in 2021.
  • "We have found a great partner in Marcone that shares our commitment to culture, values and philosophy of customer-centered service.
  • Through the combination of two premier organizations, we are excited to accelerate our growth together," said BellSimons President Floran Boland.

Munch's Supply, a Marcone Company, Acquires New Hampshire-based Total Air Supply and Spiral Air Manufacturing

Retrieved on: 
Wednesday, September 14, 2022
American Standard, Rheem, Rest, A. O. Smith, Acquisition, Trane, Goodman, Partnership, Marcone, General Electric, Supply, L-G, HVAC, Samsung, Heat, Kohler, Frigidaire, Family, Inst, Daikin, Microwave, Mitsubishi, Munch, Heating, ventilation, and air conditioning, Whirlpool, Electrolux, IPEX, Maytag

NEW LENOX, Ill., Sept. 14, 2022 /PRNewswire/ -- Munch's Supply, the HVAC division of Marcone, has acquired Total Air Supply and Spiral Air Manufacturing, including three branches servicing Manchester, Derry and Nashua, New Hampshire. This will expand Munch's geographic footprint to 74 locations serving 17 states and one Canadian province.

Key Points: 
  • NEW LENOX, Ill., Sept. 14, 2022 /PRNewswire/ -- Munch's Supply, the HVAC division of Marcone, has acquired Total Air Supply and Spiral Air Manufacturing, including three branches servicing Manchester, Derry and Nashua, New Hampshire.
  • Marcone, a leading distributor of home appliance, HVAC and plumbing repair parts and equipment across North America acquired Munch's Supply in 2021.
  • Together, the companies operate with a singular goalto become the hub for parts and services to the home for both technicians and consumers.
  • We are proud to provide our customers quality Goodman equipment along with parts and custom sheet metal, said Sue Quintiliani, owner, Total Air Supply.

Green Acre Capital Distribution Corp. Makes An Additional Investment of US$6 million, increasing its interest in the US Distribution Joint Venture to 45%

Retrieved on: 
Tuesday, September 13, 2022
Joint venture, Acre, JV, Green Acre Baháʼí School, Company, News, Johnson Brothers, Ownership, CEO, CSE, Wine, International joint venture, Inst, US, Private placement, Awareness, Creditor, SEDAR, Green Acres Mall, Private, Liquor, Drug, Cannabis, United, Humble

The Joint Venture and its resulting formation agreements are part of the previously announced Private Placement with Green Acre.

Key Points: 
  • The Joint Venture and its resulting formation agreements are part of the previously announced Private Placement with Green Acre.
  • Green Acre's investment has been funded by an option agreement with Johnson Brothers, a leading wine, spirits, and beer distributor.
  • Green Acre has funded its investment through an option agreement with Johnson Brothers, a leading wine, spirits, and beer distributor in the United States.
  • In addition, in that circumstance, Green Acre would also tender back to Humble all shares of Humble owned by Green Acre.